Monopar Therapeutics (NASDAQ:MNPR) Issues Earnings Results

Monopar Therapeutics (NASDAQ:MNPR) announced its quarterly earnings data on Thursday. The company reported ($0.72) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.82) by $0.10, FiscalAI reports.

Monopar Therapeutics Trading Up 1.9%

Shares of MNPR stock traded up $1.33 on Thursday, reaching $73.06. The company’s stock had a trading volume of 217,522 shares, compared to its average volume of 202,799. The stock’s fifty day simple moving average is $84.40 and its 200-day simple moving average is $77.39. Monopar Therapeutics has a 1 year low of $50.07 and a 1 year high of $124.82. The company has a market capitalization of $490.38 million, a price-to-earnings ratio of -33.64 and a beta of 1.62.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on MNPR shares. UBS Group set a $125.00 target price on shares of Monopar Therapeutics in a report on Thursday, July 23rd. HC Wainwright lifted their price target on shares of Monopar Therapeutics from $105.00 to $125.00 and gave the company a “buy” rating in a report on Wednesday, July 22nd. BTIG Research boosted their price target on shares of Monopar Therapeutics from $117.00 to $133.00 and gave the stock a “buy” rating in a research note on Wednesday, August 12th. Zacks Research downgraded shares of Monopar Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 13th. Finally, Cantor Fitzgerald raised Monopar Therapeutics from a “neutral” rating to an “overweight” rating and set a $119.00 target price on the stock in a report on Thursday. Seven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $122.78.

Insider Buying and Selling at Monopar Therapeutics

In related news, Director Christopher Starr sold 8,400 shares of the company’s stock in a transaction on Thursday, October 1st. The shares were sold at an average price of $78.50, for a total transaction of $659,400.00. Following the sale, the director owned 5,173 shares of the company’s stock, valued at $406,080.50. This represents a 61.89% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kim Tsuchimoto sold 2,891 shares of the company’s stock in a transaction on Wednesday, November 4th. The shares were sold at an average price of $71.26, for a total transaction of $206,012.66. Following the sale, the director directly owned 1,199 shares in the company, valued at approximately $85,440.74. The trade was a 70.68% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 51,920 shares of company stock worth $4,527,913. Company insiders own 9.70% of the company’s stock.

About Monopar Therapeutics

Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for cancer. Its pipeline includes radiopharmaceutical candidates designed to target the urokinase plasminogen activator receptor (uPAR), a protein found at elevated levels in some cancers. The company is developing MNPR-101-Zr as an imaging agent to identify uPAR-expressing tumors and MNPR-101-Lu as a potential targeted radiation therapy. These candidates are investigational and are not approved for commercial use.